Drug intelligence / Profile preview

bifonazole + triamcinolone acetonide

Development stage
Phase 3
Lead developer
Liaoning Dasheng Pharmaceutical
Modality
Small Molecules
Administration
Topical
01

Overview

Bifonazole + triamcinolone acetonide is a topical combination therapy consisting of a broad-spectrum imidazole antifungal and a potent synthetic corticosteroid. Bifonazole exerts its antifungal effect by inhibiting the synthesis of ergosterol at two distinct steps: the demethylation of lanosterol via lanosterol 14-alpha-demethylase and the conversion of HMG-CoA to mevalonate via HMG-CoA reductase. This dual inhibition is unique among imidazoles and enhances its fungicidal activity. Triamcinolone acetonide provides symptomatic relief by binding to the glucocorticoid receptor, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects. This combination is primarily indicated for the treatment of superficial fungal infections, such as tinea corporis and tinea cruris, particularly when accompanied by significant inflammation or pruritus. It is developed and manufactured by companies such as Liaoning Dasheng Pharmaceutical in China.

Other names
Bifonazole and Triamcinolone Acetonide Cream
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)GR (Glucocorticoid receptor)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on bifonazole + triamcinolone acetonide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifonazole + triamcinolone acetonide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call